Ophthotech gains commericial rights to AMD antibody

Article

Ophthotech, Biogen and PDL BioPharma have entered into an exclusive worldwide licensing agreement for an anti-angiogenesis antibody to treat age-related macular degeneration.

Ophthotech, Biogen and PDL BioPharma have entered into an exclusive worldwide licensing agreement for an anti-angiogenesis antibody to treat age-related macular degeneration (AMD).

Under the terms of the agreement, Biogen and PDL have granted Ophthotech worldwide development and commercial rights to all ophthalmic uses of volociximab, an investigational monoclonal antibody targeting (alpha)5(beta)1 integrin, a key protein involved in the formation of blood vessels.

Biogen and PDL will each receive an equity position in Ophthotech as well as a combination of development milestone payments and royalties on future product sales.

Recent Videos
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.